Your Notifications
All done, no notifications
Dr. Assoc. Prof. Ph.D, Md, Doctor Yi Hyeon Gyu

Dr. Assoc. Prof. Ph.D, Md, Doctor Yi Hyeon Gyu

Hemato Oncologist

, Ho Chi Minh, Vietnam

26 Years of experience

Speaks: English, Vietnamese

Dr. Assoc. Prof. Ph.D, Md, Doctor Yi Hyeon Gyu is currently not consulting online with MediGence
View Telemedicine Doctors

About Dr. Assoc. Prof. Ph.D, Md, Doctor Yi Hyeon Gyu

  • Dr. Yi Hyeon Gyu is a prominent oncologist and hematologist with more than two decades of achievement in academia and clinical practice.
  • Currently, he is the Head of Oncology and Hematology at the Vinmec Times City International General Hospital and Director of the Year 3 MD Program at VinUniversity.
  • Dr. Gyu has built a career in advanced cancer care, hematopoietic stem cell transplantation, and medical education, enhancing the hematology and oncology field in South Korea and Vietnam. He has 26 years of experience.

Conditions treated by Dr. Assoc. Prof. Ph.D, Md, Doctor Yi Hyeon Gyu

  • Benign and malignant hematologic disorders
  • Leukemia, lymphoma, and multiple myeloma
  • Solid organ cancers (lung, breast, colon, liver, etc.)
  • Blood and bone marrow disorders
  • Post-chemotherapy and radiotherapy complications
  • Immunological and cellular therapy indications

Area of Interest

  • Hematopoietic stem cell transplantation
  • Autologous immune enhancement therapy (AIET)
  • Targeted and personalised cancer therapy
  • Clinical oncology research and education
  • Palliative and hospice care development
  • Molecular and cellular oncology

Qualification

  • Ph.D. (Pharmacology), Inha University Graduate School, South Korea (2010)
  • M.S. (Pharmacology), Inha University Graduate School, South Korea (2001)
  • M.D., Inha University College of Medicine, South Korea (1999)
  • B.D. (Counselling Psychology), Seoul Cyber University, South Korea (2017)

Work Experiences

  • Associate Professor, Department of Hematology and Oncology, Inha University School of Medicine, South Korea
  • Vice President, Anti-Smoking Support Center, Inha University Hospital
  • Head, Hospice and Palliative Care Center, Inha University Hospital
  • Vice Director, Medical Education Center, Inha University
  • Clinical Instructor, Division of Hematology and Oncology, Seoul National University Hospital
  • Global Team of Board Certified Surgeons and Medical Specialists
  • Written Second Opinion report delivered within 5 days
  • Option to avail the Video Consultation with the Lead Doctor of the board

Access Our most trusted Medical Second Opinion

Required | alphabets and spaces
Required | A valid, working email address
Required | A valid contact

Telemedicine Doctors

CERTIFICATIONS (1)

MEMBERSHIPS (6)

  • The Korean Cancer Association
  • The Korean Cancer Study Group
  • The Korean Society of Hematology
  • The Korean Blood and Marrow Transplant Registry
  • KoNECT (Korea National Enterprise for Clinical Trials)
  • Institutional Review Board, Inha University Hospital

RESEARCH PAPERS AND PUBLICATIONS (7)

  • Jung KS, Kim YJ, Kim YK, Park SK, Kim HG, Kim SJ, Park J, Choi CW, Do YR, Kim I, Park S, Mun YC, Jeong SH, Kim MK, Yi HG, Chang MH, Kim SY, Lee JH, Jang JH. Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome Based on the International Prognostic Scoring System. Clin Lymphoma Myeloma Leuk. 2019 Jun 27. pii: S2152-2650(19)30234-4
  • Choi JY, Yi HG, Park CS, Shin DW, Kang JH. Inhibition of oxaliplatin-induced neurotoxicity by silymarin through increased expression of brain-derived neurotrophic factor and inhibition of p38-MAPK, Molecular & Cellular Toxicology 2019;15(2), 145–152
  • Lee GW, Park SW, Go SI, Kim HG, Kim MK, Min CK, Kwak JY, Bae SB, Yoon SS, Lee JJ, Kim KH, Nam SH, Mun YC, Kim HJ, Bae SH, Shin HJ, Lee JH, Park JS, Jeong SH, Lee MH, Lee HS, Park KW, Lee WS, Lee SM, Lee JO, Hyun MS, Jo DY, Lim SN, Lee JH, Kim H, Cho DY, Do YR, Kim JA, Park SK, Kim JS, Kim SJ, Yi HG, Moon JH, Choi CW, Kim SH, Kim BS, Park MR, Shim H, Song MK, Kim Y, Kim K. The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation-Ineligible Patients with Multiple Myeloma. Acta Haematol. 2018;140(3):146-156.
  • Kim WH, Bae JN, Lim J, Lee MH, Hahm BJ, Yi HG. Relationship between physicians' perceived stigma toward depression and physician referral to psycho-oncology services on an oncology/hematology ward. Psychooncology. 2018 Mar;27(3):824-830.
  • Kim MK, Kim K, Min CK, Kwak JY, Bae SB, Yoon SS, Lee JJ, Kim KH, Nam SH, Mun YC, Kim HJ, Bae SH, Shin HJ, Lee JH, Park JS, Jeong SH, Lee MH, Kim YS, Lee HS, Park KW, Lee WS, Lee SM, Lee JO, Hyun MS, Jo DY, Lim SN, Lee JH, Cho DY, Do YR, Kim JA, Park SK, Kim JS, Kim SJ, Kim H, Yi HG, Moon JH, Choi CW, Kim SH, Joo YD, Kim HG, Kim BS, Park MR, Song MK, Kim SY. A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. Oncotarget. 2017 Apr 3. doi: 10.18632/oncotarget.16790. [Epub ahead of print]
  • Yoo SH, Koh Y, Kim DY, Lee JH, Lee JH, Lee KH, Yoon SS, Park S, Park SK, Hong DS, Yi HG, Kim CS, Jang JE, Cheong JW, Moon J, Min YH, Sohn SK, Kim I; Korean Society of Blood and Marrow Transplantation. Salvage therapy for acute chemorefractory leukemia by allogeneic stem cell transplantation: the Korean experience. Ann Hematol. 2017 Apr;96(4):605-615.
  • Park YH, Yi HG, Lee MH, Kim CS, Lim JH. Prognostic Value of the Pretreatment Advanced Lung Cancer Inflammation Index (ALI) in Diffuse Large B Cell Lymphoma Patients Treated with R-CHOP Chemotherapy. Acta Haematol. 2017;137(2):76-85

Share Your Experience about Dr. Assoc. Prof. Ph.D, Md, Doctor Yi Hyeon Gyu

Write Your Review

PROCEDURES

  • Chemotherapy
  • Immunotherapy
  • Stem Cell Therapy
  • Targeted Therapy

FREQUENTLY ASKED QUESTIONS

Who is a Hemato-Oncologist?

A Hemato-Oncologist is a physician who diagnoses and treats diseases involving blood, bone marrow, and lymphatic systems, as well as types of cancers, including leukemia, lymphoma, and myeloma. They treat both benign and malignant blood disorders with medical therapies, chemotherapy, and advanced cell therapies.

What does a Hemato-Oncologist treat?

A Hemato-Oncologist treats conditions such as anemia, hemophilia, clotting disorders, leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, bone marrow failure, and other cancers of the blood and lymphatic systems.

What are the symptoms that may require an appointment with a Hemato-Oncologist?

You should see a Hemato-Oncologist if you have fatigue that cannot be explained, frequent infections, bleeding that is prolonged or difficult to stop, unexplained weight loss, fever that cannot be accounted for, and/or swollen lymph nodes, as these symptoms could be indicative of blood or oncological conditions requiring further evaluation.

What tests do Hemato-Oncologist recommend?

Common diagnostic testing recommendations may include a complete blood count (CBC) with or without a peripheral blood smear, as well as a bone marrow biopsy. You may also be recommended for genetic and/or molecular tests, flow cytometry, and imaging tests such as CT, MRI, or PET scans to help diagnose, evaluate, and/or stage hematologic cancers.

What treatment options can a hemato oncologist provide?

Treatment options available include chemotherapy, immunotherapy, targeted therapy, hormonal therapy, blood transfusions, stem cell/bone marrow transplantation, and palliative care to alleviate symptoms and maximise quality of life.